213 related articles for article (PubMed ID: 17165069)
1. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
Topf S; Simon M; Schell H; Lüftl M
Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
3. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema.
Binitha MP; Nandakumar G; Thomas D
Indian J Dermatol Venereol Leprol; 2008; 74(3):248-50. PubMed ID: 18583794
[TBL] [Abstract][Full Text] [Related]
4. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
[TBL] [Abstract][Full Text] [Related]
5. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
Rabee H; Tayem L; Gharbeyah M; Abugaber D
BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
[TBL] [Abstract][Full Text] [Related]
6. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
[TBL] [Abstract][Full Text] [Related]
8. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
9. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
Efthimiou P; Blanco M
Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
[TBL] [Abstract][Full Text] [Related]
10. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
11. [Scleromyxedema].
Neufeld M; Sunderkötter C; Moritz RKC
Hautarzt; 2018 Nov; 69(11):916-921. PubMed ID: 30135969
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
13. Scleromyxedema.
Hummers LK
Curr Opin Rheumatol; 2014 Nov; 26(6):658-62. PubMed ID: 25215418
[TBL] [Abstract][Full Text] [Related]
14. Successful intravenous immunoglobulin treatment of atypical lichen myxedematosus associated with hypothyroidism and central nervous system involvement: case report and discussion of the literature.
Macnab M; Kenny P
J Cutan Med Surg; 2013; 17(1):69-73. PubMed ID: 23364155
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.
Sroa N; Campbell S; Bechtel M
J Drugs Dermatol; 2010 Mar; 9(3):263-5. PubMed ID: 20232589
[TBL] [Abstract][Full Text] [Related]
16. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare.
Rongioletti F; Cozzani E; Parodi A
J Cutan Pathol; 2010 Oct; 37(10):1084-7. PubMed ID: 19638067
[TBL] [Abstract][Full Text] [Related]
17. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
18. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.
Körber A; Franckson T; Grabbe S; Dissemond J
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):553-4. PubMed ID: 17373996
[No Abstract] [Full Text] [Related]
19. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
20. Scleromyxedema vs scleredema: a diagnostic challenge.
Conde Fernandes I; Sanches M; Velho G; Lobo I; Alves R; Selores M
Eur J Dermatol; 2011; 21(5):822-3. PubMed ID: 21771713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
